KR20050084438A - 치환된 벤조디옥세핀 - Google Patents

치환된 벤조디옥세핀 Download PDF

Info

Publication number
KR20050084438A
KR20050084438A KR1020057011542A KR20057011542A KR20050084438A KR 20050084438 A KR20050084438 A KR 20050084438A KR 1020057011542 A KR1020057011542 A KR 1020057011542A KR 20057011542 A KR20057011542 A KR 20057011542A KR 20050084438 A KR20050084438 A KR 20050084438A
Authority
KR
South Korea
Prior art keywords
formula
benzodioxepin
compound
carbon atoms
compounds
Prior art date
Application number
KR1020057011542A
Other languages
English (en)
Korean (ko)
Inventor
티모 하인리히
헨닝 뵈트허
카이 쉬만
귄터 횔체만
크리스토프 반 암스테르담
게르트 바르토스지크
하르트무트 그라이너
크리스토프 자이프리트
미쉘 브루네
장 제일러
장 베르텔롱
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20050084438A publication Critical patent/KR20050084438A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057011542A 2002-12-20 2003-11-27 치환된 벤조디옥세핀 KR20050084438A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028596 2002-12-20
EP02028596.1 2002-12-20

Publications (1)

Publication Number Publication Date
KR20050084438A true KR20050084438A (ko) 2005-08-26

Family

ID=32668730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057011542A KR20050084438A (ko) 2002-12-20 2003-11-27 치환된 벤조디옥세핀

Country Status (16)

Country Link
US (1) US7253202B2 (es)
EP (1) EP1572685B1 (es)
JP (1) JP4575167B2 (es)
KR (1) KR20050084438A (es)
CN (1) CN1729187A (es)
AR (1) AR042554A1 (es)
AT (1) ATE350379T1 (es)
AU (1) AU2003289904B2 (es)
BR (1) BR0317342A (es)
CA (1) CA2511021C (es)
DE (1) DE50306228D1 (es)
ES (1) ES2280824T3 (es)
MX (1) MXPA05006433A (es)
PL (1) PL377325A1 (es)
WO (1) WO2004058746A1 (es)
ZA (1) ZA200505786B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227023B2 (en) * 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
PL443018A1 (pl) * 2022-12-01 2024-06-03 Uniwersytet Medyczny W Lublinie Pochodne N-((9-chloro-3,4-dihydro-2H-benzo[b][1,4]dioksepin-7-ylo)metylo)-2-(6-fluoro-1H-indol-3-ylo)etano-1-aminy, sposób ich wytwarzania i zastosowanie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700691A (en) * 1969-06-09 1972-10-24 Frosst & Co Charles E 3,3-disubstituted-3,4-dihydrobenzodioxepins
US3812150A (en) * 1969-06-09 1974-05-21 Frosst & Co 3,3-disubstituted-benzodioxepins
US3944560A (en) * 1972-05-01 1976-03-16 Merck & Co., Inc. 3-Hydroxy-3-(1,2,5-thiadiazolyloxyalkanol)-3,4-dihydro-2H-1,5-benzodioxepin products
GB2007656B (en) 1977-11-05 1982-05-19 Pfizer Ltd Therapeutic agents
DK166779B1 (da) * 1983-12-14 1993-07-12 Takeda Chemical Industries Ltd 1,5-benzoxatiepinderivater eller farmaceutisk acceptable salte deraf, samt farmaceutisk praeparat indeholdende en saadan forbindelse
JP2865341B2 (ja) * 1988-12-28 1999-03-08 サントリー株式会社 ベンゾオキサゼピン誘導体
JP3732554B2 (ja) * 1994-07-07 2006-01-05 旭化成ファーマ株式会社 新規な２，３−ジヒドロベンゾフラン誘導体、その製造方法および用途
WO1996001816A1 (fr) * 1994-07-07 1996-01-25 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau derive de 2,3-dihydrobenzofuranne, son procede de production et son utilisation
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole

Also Published As

Publication number Publication date
US7253202B2 (en) 2007-08-07
CA2511021A1 (en) 2004-07-15
AU2003289904B2 (en) 2009-12-10
PL377325A1 (pl) 2006-01-23
AU2003289904A1 (en) 2004-07-22
ZA200505786B (en) 2006-04-26
EP1572685A1 (de) 2005-09-14
ES2280824T3 (es) 2007-09-16
WO2004058746A1 (de) 2004-07-15
BR0317342A (pt) 2005-11-08
US20060167078A1 (en) 2006-07-27
CA2511021C (en) 2012-08-21
DE50306228D1 (de) 2007-02-15
AR042554A1 (es) 2005-06-22
JP2006512380A (ja) 2006-04-13
EP1572685B1 (de) 2007-01-03
CN1729187A (zh) 2006-02-01
MXPA05006433A (es) 2005-08-19
JP4575167B2 (ja) 2010-11-04
ATE350379T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
ES2427166T3 (es) Compuesto heterocíclico tricíclico novedoso
JP4897683B2 (ja) チエノピリジノン化合物及び治療方法
EP2968330B1 (en) Compounds and methods for inducing chondrogenesis
KR101013303B1 (ko) Ｐ３８ 키나제 억제제로서의 피라졸-이소퀴놀린 우레아유도체
JPS60226882A (ja) 新規ピリミドピリミジン誘導体
EP1315720A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2003212305A1 (en) Cyclic amides
US5576437A (en) 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
JP2023533943A (ja) 免疫調節剤
EP1315716A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW202245753A (zh) 用於治療疾病之類似物
JP2006522036A (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
PT736020E (pt) Compostos 6-(2-imidazolinilamino)quinolina uteis como alfa-2 adrenoceptor agonistas
EP1611126B1 (de) Chromenonindole
CN109963853B (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
KR20050084438A (ko) 치환된 벤조디옥세핀
JP2001502713A (ja) アミノ酸受容体の結合部位に対するアフィニティーを有するベンゾアキソゾール誘導体
WO2023066359A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
US10906915B2 (en) Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
DE19618999A1 (de) Neue Benzothiazolinone
JPH04330078A (ja) 抗緑内障剤としての置換チエノ［２，３−ｂ］［１，４］チアジン−６−スルホンアミド類
DE19618970A1 (de) Neue Thiazolopyridine
EP0500319A1 (en) Oxazinobenzazole compounds
CA3155338A1 (en) Xanthine cb1 inhibitors
JPH0673008A (ja) アンジオテンシンｉｉ拮抗性ピリジン誘導体

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid